TORONTO AND CAMBRIDGE, MA, January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10:00 a.m. EST.
The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal.
About Deep Genomics
Deep Genomics combines artificial intelligence (AI) and RNA biology to program and prioritize transformational AI-enabled therapies for almost any gene in any genetic condition. The proprietary platform, called the AI Workbench, allows Deep Genomics to decode vast amounts of data on RNA biology, identify novel targets for genetic diseases, and produce therapeutic programs with a high success rate. Almost everyone will suffer from a genetic condition at some point in their life, and Deep Genomics aims to be there for them with a genetically precise therapy. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter.
Contact:
Deep Genomics
press@deepgenomics.com